Slingshot Biosciences and Cellares Team Up to Revolutionize QC in Cell Therapy

Slingshot Biosciences and Cellares have announced a strategic partnership aimed at elevating the standards of automated quality control (QC) in cell therapy manufacturing. This collaboration integrates Slingshot’s TruCytes Biomarker controls into Cellares’ innovative testing platform, Cell Q. By enhancing precision and scalability, the partnership seeks to address the complexities of modern cell therapy production.

Cellares, recognized as the first Integrated Development and Manufacturing Organization (IDMO), has developed Cell Q, the industry’s first fully automated QC testing platform. This platform is designed to seamlessly integrate with Cellares’ automated manufacturing system, known as the Cell Shuttle, which has received acknowledgment from the U.S. FDA under the Advanced Manufacturing Technology (AMT) program.

The TruCytes biomarker controls introduced by Slingshot represent a significant advancement in standardised reference materials for flow cytometry. These controls mimic the optical and biochemical properties of actual cells while eliminating variability associated with donor samples. This innovation ensures greater precision and reproducibility in analytical workflows, which is critical for maintaining consistent quality in cell therapy production.

Advancements in Automated Quality Control

Integrating TruCytes controls into Cellares’ Cell Q platform aims to reduce failure rates and enhance data consistency. This collaboration also seeks to streamline production processes across multiple manufacturing sites. According to Fabian Gerlinghaus, CEO and Co-Founder of Cellares, “Slingshot’s TruCytes controls provide standardised, ready-to-run inputs for QC across instruments and sites, eliminating the variability and supply constraints that come with donor-based materials. Integrating them into our Cell Q platform extends the same level of automation, reliability, and traceability that define the Cell Shuttle.”

The partnership is a direct response to the increasing complexity of flow cytometry technologies. Glenn Bilawsky, CEO of Slingshot Biosciences, emphasized the significance of this collaboration in addressing the demands of global cell therapy manufacturing. He stated that the integration of TruCytes with automated QC systems enables continuous and reliable testing on an industrial scale.

As both companies move forward, the collaboration is expected to set new benchmarks for quality assurance in cell therapy, ultimately benefiting the broader healthcare landscape. In a market that increasingly relies on automated solutions, this partnership stands poised to enhance the efficiency and reliability of cell therapy manufacturing processes, ensuring that patients receive the highest quality treatments available.

With the growing importance of advanced manufacturing technologies, the union between Slingshot and Cellares marks a notable step forward in the evolution of cell therapy production. As they continue to innovate, both companies are likely to play a crucial role in shaping the future of this dynamic industry.